InsidersTradesSigma
申报总数
公司
▲ 买入（1 笔）
▼ 卖出（0 笔）
内部人交易记录
首席财务官已披露买入
1
已披露卖出
0
T+90 胜率
0%
T+90 平均收益
-21.6%
基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
无可用的信号评分。
Discover the full record of transactions filed by Mathiesen Jeffrey S, 首席财务官. Director active across 3 companies, notably Helius Medical Technologies, INC.. Aggregated, 9 disclosures have been logged. Breakdown: 1 buy · 0 sell. Total volume traded: €14k. History available since 25 May 2021. The latest transaction was filed on 3 April 2026 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Mathiesen Jeffrey S
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报9 总计
41,929 股0Common StockSEC:0001296853-26-000001:0
27,778 股0Common StockSEC:0001213900-25-015155:0
20,576 股0Common StockSEC:0001213900-23-021351:0
29,240 股0Common StockSEC:0001596771-22-000017:0
8,011 股0Class A Common StockSEC:0001209191-22-011221:0
3,000 股@ US$5.3098100.0% 占其流量Class A Common StockSEC:0001209191-21-070472:0
标准退出：2022年3月17日 (T+90)
4,592 股0Common StockSEC:0001596771-21-000039:0
4,316 股0Common StockSEC:0001437749-21-013593:0
937 股0Class A Common StockSEC:0001209191-21-036235:0
9 条申报中的 9 条
About Mathiesen Jeffrey S
Jeffrey S. Mathiesen is the Chief Financial Officer and Treasurer at Helius Medical Technologies, Inc., Panbela Therapeutics, Inc., and NeuroOne Medical Technologies Corp. He oversees financial operations and contributes to the overall strategy of these companies.
